Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OTX-TPa ~4µg/day over 2 mos. with natural tears · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| OTX-TPa | EXPERIMENTAL | OTX-TPa is a hydrogel punctum plug eluting travoprost in sustained release of \~4µg/day over approximately 2 months. For study masking purposes, subjects in this arm will also have natural tears drops administered. |
| OTX-TPb | EXPERIMENTAL | OTX-TPb is a hydrogel punctum plug eluting travoprost in sustained release of \~3µg/day over approximately 3 months. For study masking purposes, subjects in this arm will also have natural tears drops administered. |
| Timolol | ACTIVE_COMPARATOR | Timolol Maleate (0.5%) ophthalmic solution dosed twice daily (BID). For study masking purposes, subjects in this arm will also have a hydrogel punctum plug with no drug placed for approximately 3 months. |
| Name | Type | Description |
|---|---|---|
| OTX-TPa ~4µg/day over 2 mos. with natural tears drops | DRUG | OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of \~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops. |
| OTX-TPb ~3µg/day over 3 months with natural tears drops | DRUG | OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of \~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops. |
| Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug | DRUG | Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed. |
Inclusion Criteria: * Subject must be greater than or equal to 18 years of age at Screening. * Subject must have a documented diagnosis of ocular hypertension, open angle glaucoma. * Subject has a mean baseline (Day -7 and Day 0) Hour 0 (T0) untreated IOP of ≥ 24 mm Hg and ≤ 34 mm Hg in each eye, a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 5 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |